(Q37371383)

20 August 2017

1 reference

title

Beyond immunosuppression - challenges in the clinical management of lupus nephritis (English)

1 reference

20 August 2017

1 reference

S Masood

1

1 reference

20 August 2017

D Jayne

series ordinal

2

1 reference

20 August 2017

Y Karim

series ordinal

3

1 reference

20 August 2017

publication date

1 February 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

18

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

106-115

1 reference

The NIH pulse cyclophosphamide regime: the end of an era?

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Optimal care of lupus nephritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Lupus nephritis: current issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Serum creatinine is a poor marker of GFR in nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Estimating renal function in lupus nephritis: comparison of the Modification of Diet in Renal Disease and Cockcroft Gault equations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Estimation of glomerular filtration rate in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Chromium-51 ethylenediamine tetraacetic acid glomerular filtration rate: a better predictor than glomerular filtration rate calculated by the Cockcroft-Gault formula for renal involvement in systemic lupus erythematosus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Can spot urine protein/creatinine ratio replace 24 h urine protein in usual clinical nephrology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

How to monitor SLE in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Urinary TWEAK and the activity of lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Urinary proteomic profiles distinguish between active and inactive lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approach to perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Statins for improving renal outcomes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

The bimodal mortality pattern of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Common variable immunodeficiency in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Anti-inflammatory and immunosuppressive drugs and reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308095330

21 January 2018

Identifiers

DOI

10.1177/0961203308095330

1 reference

20 August 2017

1 reference